DRUGS & AGING

Scope & Guideline

Transforming drug therapies to enhance quality of life in older adults.

Introduction

Welcome to the DRUGS & AGING information hub, where our guidelines provide a wealth of knowledge about the journal’s focus and academic contributions. This page includes an extensive look at the aims and scope of DRUGS & AGING, highlighting trending and emerging areas of study. We also examine declining topics to offer insight into academic interest shifts. Our curated list of highly cited topics and recent publications is part of our effort to guide scholars, using these guidelines to stay ahead in their research endeavors.
LanguageEnglish
ISSN1170-229x
PublisherADIS INT LTD
Support Open AccessNo
CountryUnited Kingdom
TypeJournal
Convergefrom 1991 to 2024
AbbreviationDRUG AGING / Drugs Aging
Frequency12 issues/year
Time To First Decision-
Time To Acceptance-
Acceptance Rate-
Home Page-
Address5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND

Aims and Scopes

The journal 'DRUGS & AGING' aims to address the complex pharmacotherapy needs of older adults, focusing on optimizing medication use while minimizing potential adverse effects. Its scope encompasses various aspects of drug therapy in geriatric populations, emphasizing evidence-based practices and interdisciplinary approaches.
  1. Geriatric Pharmacotherapy:
    Research dedicated to understanding the pharmacokinetics and pharmacodynamics of drugs in older adults, including how aging affects drug metabolism and response.
  2. Polypharmacy and Deprescribing:
    Focused studies on the prevalence and effects of polypharmacy in older adults, including strategies for deprescribing potentially inappropriate medications to improve patient outcomes.
  3. Chronic Disease Management:
    Investigations into the management of chronic conditions prevalent among older adults, such as diabetes, hypertension, and cardiovascular diseases, with an emphasis on tailored pharmacological interventions.
  4. Adverse Drug Reactions and Drug Interactions:
    Research aimed at identifying and mitigating adverse drug reactions and interactions, especially in the context of multimorbidity and polypharmacy.
  5. Quality of Life and Patient-Centered Care:
    Studies that explore the impact of pharmacotherapy on the quality of life, emphasizing patient perspectives and outcomes in the context of aging.
  6. Innovative Therapeutics:
    Research into newer therapeutic agents and treatment modalities, including biologics and targeted therapies, specifically for older populations.
The landscape of research within 'DRUGS & AGING' is dynamic, with several emerging themes reflecting current clinical challenges and innovations in geriatric pharmacotherapy.
  1. Digital Health and Telemedicine:
    An increasing number of studies are focusing on the role of digital tools and telemedicine in managing medications and health outcomes for older adults, highlighting the need for innovative approaches in a rapidly changing healthcare environment.
  2. Patient-Reported Outcomes and Quality of Life:
    There is a growing emphasis on incorporating patient-reported outcomes in research, reflecting a trend towards more holistic approaches to treatment that prioritize the patient's perspective on their health and medication.
  3. Pharmacogenomics in Aging:
    Emerging interest in pharmacogenomic studies to personalize medication regimens for older adults, aiming to optimize therapeutic efficacy while minimizing adverse effects.
  4. Use of Cannabis and Cannabinoids:
    Research on the use of medical cannabis and cannabinoids among older adults is gaining traction, particularly in relation to pain management and quality of life improvements.
  5. Focus on Frailty and Comprehensive Geriatric Assessment:
    An increasing number of studies are honing in on frailty as a critical factor in medication management, advocating for comprehensive geriatric assessments to tailor pharmacological treatments.

Declining or Waning

As the journal 'DRUGS & AGING' evolves, certain research themes appear to be declining in prominence. This may reflect shifts in clinical priorities, emerging evidence, or changing healthcare landscapes affecting older adults.
  1. Anticholinergic Burden Studies:
    While still relevant, there has been a noticeable decrease in dedicated studies focusing solely on anticholinergic burden, suggesting a potential shift towards broader polypharmacy and deprescribing discussions.
  2. Traditional Pain Management Approaches:
    Research centered around traditional pain management strategies, particularly opioid use, has seen reduced focus, likely due to increasing scrutiny over opioid prescribing and a shift towards non-pharmacological management.
  3. Longitudinal Studies of Aging and Medication Use:
    Fewer long-term studies tracking medication use and outcomes in aging populations indicate a potential waning interest in longitudinal methodologies in favor of more immediate, intervention-focused research.

Similar Journals

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY

Exploring Innovations in Drug Action and Safety
Publisher: WILEYISSN: 1742-7835Frequency: 12 issues/year

BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, published by WILEY, serves as a vital resource in the fields of medicine, pharmacology, and toxicology. With an ISSN of 1742-7835 and E-ISSN 1742-7843, this journal has established a robust reputation, reflected in its Q2 classification across its categories in 2023. It aims to disseminate high-quality research and reviews that bridge the gap between basic scientific findings and clinical applications. Operating from the United States with an address at 111 RIVER ST, HOBOKEN 07030-5774, NJ, this journal focuses on the intersection of drug action and toxicity, making it an essential platform for researchers, healthcare professionals, and students. With a converged publication timeline from 2004 to 2024, BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY continues to make significant contributions to understanding pharmacological treatments and toxicological challenges. Open access options are available to broaden the reach and impact of its published work.

Current Geriatrics Reports

Connecting professionals with the latest developments in geriatrics.
Publisher: SPRINGERISSN: Frequency: 4 issues/year

Current Geriatrics Reports is a pivotal journal published by SPRINGER, dedicated to disseminating cutting-edge research and insights in the dynamic field of geriatrics and gerontology. Launched in 2014 and ongoing until 2024, this journal plays a critical role in addressing the complex needs and challenges faced by the aging population. Although it currently holds a Q4 quartile ranking in its category and occupies the 84th position out of 116 in the Scopus metrics for Medicine, Geriatrics, and Gerontology, it serves as a vital platform for emerging research that shapes clinical practices and policy-making. Researchers, professionals, and students alike will find Current Geriatrics Reports to be an invaluable resource for staying updated on advancements, best practices, and innovations in geriatric care. While the journal is not open access, it continues to impact the field significantly and enrich contemporary discussions surrounding aging.

PHARMAZIE

Transforming pharmaceutical practices through research.
Publisher: AVOXA-MEDIENGRUPPE DEUTSCHER APOTHEKER GMBHISSN: 0031-7144Frequency: 12 issues/year

PHARMAZIE is a prestigious, peer-reviewed journal published by AVOXA-MEDIENGRUPPE DEUTSCHER APOTHEKER GMBH, focusing on the dynamic field of pharmaceutical science since its inception in 1947. With its ISSN 0031-7144 and a current impact factor placing it in the Q2 category of Pharmaceutical Science journals, PHARMAZIE has established itself as a pivotal resource for researchers, practitioners, and students alike. The journal emphasizes the dissemination of high-quality, original research in pharmacology, toxicology, and pharmaceutics, contributing to the advancement of knowledge and innovation in these fields. While currently not open access, the journal maintains a commendable Scopus rank of #94 out of 183 in its category, highlighting its relevance and appeal to the academic community. With a commitment to bridging the gap between research and practical applications, PHARMAZIE plays a crucial role in shaping the future of pharmaceutical practices and policies.

Drug Healthcare and Patient Safety

Championing safe medication practices for all.
Publisher: DOVE MEDICAL PRESS LTDISSN: 1179-1365Frequency: 1 issue/year

Drug Healthcare and Patient Safety is a premier Open Access journal, published by DOVE MEDICAL PRESS LTD since 2009, dedicated to advancing the understanding and practices surrounding medication safety and healthcare delivery. With its ISSN 1179-1365 and E-ISSN matching, this New Zealand-based journal not only fosters global discourse but also prioritizes the dissemination of research that intersects both health policy and pharmacology. Categorized as Q2 in Health Policy and Q3 in Pharmacology for the year 2023, it occupies a notable position within the academic community, as reflected by its Scopus rankings, which place it in the 66th and 45th percentiles of its respective categories. Drug Healthcare and Patient Safety aims to provide a platform for researchers, practitioners, and students to share innovative findings, promote safe medication practices, and explore the implications of health policy on patient outcomes. As an Open Access journal, it ensures that vital research is accessible to a wider audience, making significant contributions to the ongoing dialogue in the fields of healthcare and pharmacovigilance.

BMC Geriatrics

Transforming insights into impactful geriatric practices.
Publisher: BMCISSN: Frequency: 1 issue/year

BMC Geriatrics is a leading open-access journal dedicated to advancing the field of geriatrics and gerontology. Published by BMC, this esteemed journal has been at the forefront of research since its inception in 2001, providing a vital platform for sharing innovative studies and insights that address the complexities of aging. With an impressive Q1 ranking in the 2023 category of Geriatrics and Gerontology and a solid Scopus ranking at #40 out of 116, BMC Geriatrics showcases high-impact research that influences clinical practices and policy-making. As a fully open-access publication, it ensures that groundbreaking research is freely available to researchers, practitioners, and students alike, promoting the diffusion of knowledge across the global healthcare community. This journal is crucial for anyone interested in the latest developments in elderly care, health issues affecting aging populations, and innovative interventions designed to improve quality of life among older adults.

JOURNAL OF ONCOLOGY PHARMACY PRACTICE

Connecting research and practice in the fight against cancer.
Publisher: SAGE PUBLICATIONS LTDISSN: 1078-1552Frequency: 8 issues/year

JOURNAL OF ONCOLOGY PHARMACY PRACTICE, published by SAGE PUBLICATIONS LTD, is a pivotal resource in the fields of oncology, pharmacology, and medicine, with a dedicated focus on the evolving discipline of oncology pharmacy. Based in the United Kingdom, this journal has been diligently serving its readers since 1995 and continues to explore the intersection of pharmaceutical care and cancer treatment, showcasing innovative practices, research findings, and clinical advancements that are indispensable for healthcare professionals, researchers, and students alike. Although not an open-access journal, it holds a respectable Category Quartile Q3 ranking across its various fields, including Medicine, Oncology, and Pharmacology, indicating its relevance in nurturing academic discourse and addressing critical issues in cancer care. With an ISSN of 1078-1552 and E-ISSN of 1477-092X, the journal invites contributions that enhance the understanding of pharmaceutical interventions in oncology, aiming to improve therapeutic outcomes and patient care. Join a global community of professionals committed to excellence in oncology pharmacy practice and stay informed with cutting-edge research and reviews that significantly impact patient healthcare strategies.

Journal of Frailty & Aging

Unveiling insights into the aging experience.
Publisher: SPRINGER BASEL AGISSN: 2260-1341Frequency: 4 issues/year

Journal of Frailty & Aging, published by SPRINGER BASEL AG, is a leading platform dedicated to advancing research in the fields of aging, geriatrics, and gerontology. With an ISSN of 2260-1341 and an E-ISSN of 2273-4309, this journal has established itself as a pivotal resource for scholars and practitioners aiming to explore the complexities of frailty and its impact on aging populations. As of 2023, it proudly holds a Q3 classification in Aging and Q2 classifications in both Geriatrics and Gerontology, as well as Physiology (medical), alongside a notable Q1 ranking in Medicine (miscellaneous). The journal's Scopus ranks further reflect its quality and relevance, with rankings as high as #22 in Aging within the Biochemistry, Genetics and Molecular Biology category. The Journal of Frailty & Aging invites contributions that illuminate contemporary challenges and innovations in the field, offering Open Access to enhance the dissemination of knowledge. By publishing rigorous research and impactful reviews, the journal strives to foster a deeper understanding of health and well-being in older adults, making it an essential resource for researchers, healthcare professionals, and students engaged in this vital area of study.

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS

Fostering knowledge in pharmacology for real-world impact.
Publisher: WILEY-HINDAWIISSN: 0269-4727Frequency: 1 issue/year

JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS, an esteemed publication in the field of pharmacology, is published by Wiley-Hindawi and has been at the forefront of clinical research since its inception in 1976. Operating primarily from the United Kingdom, this journal features a diverse array of articles that encompass both fundamental and practical aspects of clinical pharmacy, thereby supporting the advancement of therapeutic practices. With an ISSN of 0269-4727 and an E-ISSN of 1365-2710, it is indexed in key databases and holds respectable ranks within its categories; achieving Q3 in Pharmacology and Q2 in Medical Pharmacology in the latest quartile rankings. Its Scopus ranking reflects both its quality and relevance, being positioned in the 55th percentile for medical pharmacology and the 45th for pharmacology, toxicology, and pharmaceutics. Although it does not currently operate under an Open Access model, the journal's extensive readership and rigorous peer-review process ensure that the latest research reaches practitioners and academics alike. With a commitment to bridging the gap between pharmacological science and clinical practice, the JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS remains a critical resource for professionals striving to enhance patient outcomes through informed medication management.

Canadian Geriatrics Journal

Advancing geriatric knowledge for a healthier tomorrow.
Publisher: MULTIMED INCISSN: Frequency: 4 issues/year

Canadian Geriatrics Journal, published by MULTIMED INC, is a prominent platform dedicated to advancing the field of geriatrics and gerontology. With its esteemed status as a Q2 journal in both Geriatrics and Gerontology categories for 2023, it ranks favorably within the academic community, holding a 73rd percentile in Nursing Gerontology and a 59th percentile in Medicine Geriatrics and Gerontology according to Scopus metrics. Since its inception in 2011, the journal has aimed to foster innovation and disseminate pivotal research that addresses the complexities of aging populations. Researchers, healthcare professionals, and students interested in the intricacies of geriatric care will find a wealth of open-access resources that contribute significantly to enhancing practice and care methodologies in Canada and beyond. With its address located at 66 Martin St, Toronto, ON L9T 2R2, Canada, the journal stands as a vital resource for stakeholders in the geriatric field.

Expert Opinion On Drug Safety

Championing Excellence in Drug Safety Practices
Publisher: TAYLOR & FRANCIS LTDISSN: 1474-0338Frequency: 6 issues/year

Expert Opinion on Drug Safety is a prestigious academic journal dedicated to advancing knowledge in the fields of drug safety and pharmacology. Published by Taylor & Francis Ltd, this journal serves as an essential resource for researchers and professionals seeking to explore the complexities of drug interactions, adverse effects, and risk management. With an impressive impact factor and recognized as a Q1 journal in both the Medicine (Miscellaneous) and Pharmacology (Medical) categories, it ranks favorably at #78 out of 272 in Scopus, placing it in the 71st percentile among its peers. Operating under a rigorous peer-review process, the journal publishes original research, expert reviews, and opinion pieces that contribute to a deeper understanding of drug safety practices. While not an open access journal, it remains a vital platform for disseminating pivotal findings and fostering scholarly dialogue, ensuring that critical insights reach a global audience. With continuous publication from 2002 to 2024, Expert Opinion on Drug Safety is a key reference for anyone involved in pharmaceutical research, healthcare practice, or drug regulation.